Kendra K Radtke1, Anneke C Hesseling2, J L Winckler2, Heather R Draper2, Belen P Solans1, Stephanie Thee2,3, Lubbe Wiesner4, Louvina E van der Laan2, Barend Fourie2, James Nielsen5, H Simon Schaaf2, Radojka M Savic1, Anthony J Garcia-Prats2,6. 1. Department of Bioengineering and Therapeutic Sciences, University of California-San Francisco, San Francisco, California, USA. 2. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. 3. Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin , Berlin, Germany. 4. Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa. 5. Department of Pediatrics, New York University School of Medicine, New York, New York, USA. 6. University of Wisconsin, Department of Pediatrics, Madison, Wisconsin, USA.
Abstract
BACKGROUND: Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB. METHODS: Pharmacokinetic data were pooled from 2 observational studies in South African children with RR-TB routinely treated with oral moxifloxacin once daily. The population pharmacokinetics and Fridericia-corrected QT (QTcF)-interval prolongation were characterized in NONMEM. Pharmacokinetic simulations were performed to predict expected exposure and optimal weight-banded dosing. RESULTS: Eighty-five children contributed pharmacokinetic data (median [range] age of 4.6 [0.8-15] years); 16 (19%) were aged <2 years, and 8 (9%) were living with human immunodeficiency virus (HIV). The median (range) moxifloxacin dose on pharmacokinetic sampling days was 11 mg/kg (6.1 to 17). Apparent clearance was 6.95 L/h for a typical 16-kg child. Stunting and HIV increased apparent clearance. Crushed or suspended tablets had faster absorption. The median (range) maximum change in QTcF after moxifloxacin administration was 16.3 (-27.7 to 61.3) ms. No child had QTcF ≥500 ms. The concentration-QTcF relationship was nonlinear, with a maximum drug effect (Emax) of 8.80 ms (interindividual variability = 9.75 ms). Clofazimine use increased Emax by 3.3-fold. Model-based simulations of moxifloxacin pharmacokinetics predicted that current dosing recommendations are too low in children. CONCLUSIONS: Moxifloxacin doses above 10-15 mg/kg are likely required in young children to match adult exposures but require further safety assessment, especially when coadministered with other QT-prolonging agents.
BACKGROUND: Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB. METHODS: Pharmacokinetic data were pooled from 2 observational studies in South African children with RR-TB routinely treated with oral moxifloxacin once daily. The population pharmacokinetics and Fridericia-corrected QT (QTcF)-interval prolongation were characterized in NONMEM. Pharmacokinetic simulations were performed to predict expected exposure and optimal weight-banded dosing. RESULTS: Eighty-five children contributed pharmacokinetic data (median [range] age of 4.6 [0.8-15] years); 16 (19%) were aged <2 years, and 8 (9%) were living with human immunodeficiency virus (HIV). The median (range) moxifloxacin dose on pharmacokinetic sampling days was 11 mg/kg (6.1 to 17). Apparent clearance was 6.95 L/h for a typical 16-kg child. Stunting and HIV increased apparent clearance. Crushed or suspended tablets had faster absorption. The median (range) maximum change in QTcF after moxifloxacin administration was 16.3 (-27.7 to 61.3) ms. No child had QTcF ≥500 ms. The concentration-QTcF relationship was nonlinear, with a maximum drug effect (Emax) of 8.80 ms (interindividual variability = 9.75 ms). Clofazimine use increased Emax by 3.3-fold. Model-based simulations of moxifloxacin pharmacokinetics predicted that current dosing recommendations are too low in children. CONCLUSIONS: Moxifloxacin doses above 10-15 mg/kg are likely required in young children to match adult exposures but require further safety assessment, especially when coadministered with other QT-prolonging agents.
Authors: Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling Journal: Clin Infect Dis Date: 2014-10-30 Impact factor: 9.079
Authors: Andreas H Diacon; Rodney Dawson; Florian von Groote-Bidlingmaier; Gregory Symons; Amour Venter; Peter R Donald; Christo van Niekerk; Daniel Everitt; Jane Hutchings; Divan A Burger; Robert Schall; Carl M Mendel Journal: Am J Respir Crit Care Med Date: 2015-04-15 Impact factor: 21.405
Authors: Andrew J Nunn; Patrick P J Phillips; Sarah K Meredith; Chen-Yuan Chiang; Francesca Conradie; Doljinsuren Dalai; Armand van Deun; Phan-Thuong Dat; Ngoc Lan; Iqbal Master; Tesfamarium Mebrahtu; Daniel Meressa; Ronelle Moodliar; Nosipho Ngubane; Karen Sanders; Stephen Bertel Squire; Gabriela Torrea; Bazarragchaa Tsogt; I D Rusen Journal: N Engl J Med Date: 2019-03-13 Impact factor: 91.245
Authors: Simbarashe P Zvada; Paolo Denti; Hennie Geldenhuys; Sandra Meredith; Danelle van As; Mark Hatherill; Willem Hanekom; Lubbe Wiesner; Ulrika S H Simonsson; Amina Jindani; Thomas Harrison; Helen M McIlleron Journal: Antimicrob Agents Chemother Date: 2012-05-14 Impact factor: 5.191
Authors: Stefan Willmann; Matthias Frei; Gabriele Sutter; Katrin Coboeken; Thomas Wendl; Thomas Eissing; Jörg Lippert; Heino Stass Journal: CPT Pharmacometrics Syst Pharmacol Date: 2019-08-07
Authors: N A H Seneadza; S Antwi; H Yang; A Enimil; A Dompreh; L Wiesner; C A Peloquin; M Lartey; M Lauzardo; A Kwara Journal: Int J Tuberc Lung Dis Date: 2021-01-01 Impact factor: 2.373